Jennifer Armstrong - Aralez Pharmaceuticals President
President
Ms. Jennifer Lou Armstrong is Executive Vice President Human Resources and Administration of the Company, since February 5, 2016. Ms. Armstrong was previously the Executive Vice President, Human Resources and Administration of Pozen from June 2015 through February 5, 2016. Prior to joining Pozen, she served as Senior Vice President of Human Resources at Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, from July 2009 to March 2015. Prior to that, she served at Senior Vice President of Human Resources and Corporationrationrate Communications at Genaera Corporationrationration, a specialty biopharmaceutical company, from January 1998 to May 2009. On June 12, 2009, Genaera Corporation transferred all of its assets and liabilities to the Genaera Liquidating Trust and filed a Certificate of Dissolution with the Delaware Secretary of State pursuant to the Plan of Complete Liquidation and Dissolution adopted at a special meeting of stockholders since 2016.
| Age | 44 |
| Tenure | 8 years |
| Phone | 905-876-1118 |
| Web | http://www.aralez.com |
Aralez Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (6.75) % which means that it has lost $6.75 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (262.08) %, meaning that it created substantial loss on money invested by shareholders. Aralez Pharmaceuticals' management efficiency ratios could be used to measure how well Aralez Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 274.57 M in liabilities. Aralez Pharmaceuticals has a current ratio of 0.78, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aralez Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aralez Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aralez Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aralez to invest in growth at high rates of return. When we think about Aralez Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Robert Ferris | Axalta Coating Systems | N/A | |
| Stephen Rolfs | Sensient Technologies | 59 | |
| Darian Rich | Barrick Gold Corp | 63 | |
| Kimberly Morin | Sensient Technologies | 53 | |
| Tobin Tornehl | Sensient Technologies | 50 | |
| Robert Slone | Stepan Company | 45 | |
| Jason Cho | Eldorado Gold Corp | N/A | |
| Kevin Thomson | Barrick Gold Corp | 67 | |
| Luis Rojo | Stepan Company | 51 | |
| Krista Muhr | Eldorado Gold Corp | N/A | |
| Debra Stefaniak | Stepan Company | 59 | |
| Arthur Mergner | Stepan Company | 60 | |
| Steve Morris | Sensient Technologies | 60 | |
| Gautam Grover | Sensient Technologies | 47 | |
| David Heflin | Axalta Coating Systems | N/A | |
| Robert Roop | Axalta Coating Systems | N/A | |
| Greg Walker | Barrick Gold Corp | 59 | |
| Craig Mitchell | Sensient Technologies | 59 | |
| Sean Moriarty | Stepan Company | 51 | |
| Troy Johnson | Apogee Enterprises | 50 | |
| Frank Pacholec | Stepan Company | 62 | |
Management Performance
| Return On Equity | -262.08 | |||
| Return On Asset | -6.75 |
Aralez Pharmaceuticals Leadership Team
Elected by the shareholders, the Aralez Pharmaceuticals' board of directors comprises two types of representatives: Aralez Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aralez. The board's role is to monitor Aralez Pharmaceuticals' management team and ensure that shareholders' interests are well served. Aralez Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aralez Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Martin Thrasher, Independent Director | ||
| Jason Aryeh, Independent Director | ||
| Arthur Kirsch, Independent Chairman of the Board | ||
| Jennifer Armstrong, Executive Vice President - Human Resources and Administration | ||
| Neal Fowler, Independent Director | ||
| James Tursi, Chief Medical Officer | ||
| Seth Rudnick, Independent Director | ||
| Scott Charles, CFO, Senior Vice President | ||
| Mark Glickman, Chief Commercial Officer | ||
| Robert Harris, Independent Director | ||
| Eric Trachtenberg, Chief Compliance Officer, General Counsel, Corporate Secretary | ||
| Kenneth Lee, Lead Independent Director | ||
| Andrew Koven, President Chief Business Officer | ||
| Adrian Adams, CEO, Director | ||
| Michael Kaseta, Head of Finance and Interim CFO, Principal Financial Officer, Principal Accounting Officer |
Aralez Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aralez Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -262.08 | |||
| Return On Asset | -6.75 | |||
| Profit Margin | (99.50) % | |||
| Operating Margin | (45.33) % | |||
| Current Valuation | 233.57 M | |||
| Shares Outstanding | 67.19 M | |||
| Shares Owned By Insiders | 9.58 % | |||
| Shares Owned By Institutions | 8.27 % | |||
| Number Of Shares Shorted | 2.97 M | |||
| Price To Earning | (0.85) X |
Pair Trading with Aralez Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aralez Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aralez Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Aralez Stock
If you are still planning to invest in Aralez Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aralez Pharmaceuticals' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |